A multicentre, Open Label, Treatment Protocol of the Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS)

Trial Profile

A multicentre, Open Label, Treatment Protocol of the Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS)

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Sep 2016

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions
  • Acronyms ACCESS
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 27 Sep 2016 Results of pooled analysis from this and other nine trials (CLASSIC I and II, GAIN, CHARM, EXTEND, CARE, ACCESS, ADHERE) assessing the risk of serious and opportunistic infections in patients with treated with adalimumab (n=2266) published in the American Journal of Gastroenterology.
    • 05 Nov 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top